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Abstract 
Christopher R. Gough 
PROTEIN-BASED NANOFIBERS AND THIN FILMS FOR DRUG DELIVERY 
APPLICATIONS 
2020-2021 
Xiao Hu, Ph.D. 
Master of Science in Pharmaceutical Sciences 
 
Corn zein and silk are both widely available, easy to extract proteins making them 
valuable replacements for synthetics. Zein and silk are also promising biomaterials in 
several applications. This work explores the use of both proteins as drug delivery vehicles 
by loading 1-Dimensional micro-nanofibers and 2-Dimensional thin films with model 
drugs or the topical therapeutic sodium citrate. Using a formic acid solvent, powdered 
zein protein or silk fibers were dissolved into solution and then casted into 2D films or 
spun into 1D fibers through air-spraying. During dissolution, therapeutic products are 
added. SEM images showed that fibers maintain their small diameter and porous network 
at lower amounts of therapeutics. Structural characterization showed that therapeutics 
could interact and influence secondary protein structure in porous fibers, but not flat 
films. This interaction improves the thermal integrity of most samples and allowed for 
greater control of the release of therapeutics from the biomaterial. In summary, the 
geometry of the biomaterials played an important role in allowing biophysical and 
biochemical interactions between the therapeutics and the protein structure of the 
biomaterials. By understanding these interactions, there is more control over material 
properties and release kinetics. Meanwhile, the fabrication process showed no hindrance 
on the biocompatibility of the biomaterials in a human cell line.  
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1.1 Biopolymers Within the Scope of Biomedical Applications 
Biopolymers from nature, especially proteins and polysaccharides, have gained 
interest in recent times due to their abundance, low cost, biocompatibility, and tunable 
morphological and physical properties1-5. These biopolymers have been used for the 
development of membranes and nanofibers for biomedical applications including tissue 
engineering scaffolds 6, 7 and for drug delivery 8. Biopolymers are extremely versatile; 
silks have extremely high tensile strength while maintaining high elasticity and chitin is 
used for structural integrity and protection in several insects, for examples. To adapt 
these materials for biomedical applications, however, several methodologies are used to 
tune the physiochemical properties of these materials to suit specific applications. 
Natural proteins and polysaccharides are relatively inexpensive to regenerate into 
more useful forms. While this economic advantage is already attractive, the main 
advantage of biopolymers is their inherent biodegradability and biocompatibility. A 
critical parameter for the success off drug delivery and tissue engineering applications is 
minimizing adverse reactions from the host immune response. Through natural enzymes 
found in the body, biopolymers are degradable and there is little accumulation of toxic 
by-products 9, 10. 
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Fibrous materials, especially nanofibers, are becoming increasingly utilized in 
biomedical research due to their high surface-area-to-volume ratio, mechanical strength, 
porosity and tunability. Because of the ease of working with natural biopolymers and 
their biocompatibility and biodegradability, they are an attractive source for nanofiber 
fabrication. Natural enzymes, some in vivo, can degrade fibers into nontoxic metabolites 
that are reabsorbed by the body. Natural biopolymers can even improve select 
applications, such as enhancing cell attachment to tissue engineering scaffolds and 
increase cell proliferation due to native cell attachment motifs 11, 12. The ease and 
practicality of natural biopolymers give them appeal in medical applications. Despite 
these advantages, biopolymer-based fibers remain inferior to many synthetic polymers in 
their mechanical properties. To improve these properties, natural biopolymer-based fibers 
can be further modified by crosslinking, blending with other polymers, or additives to 
form a tunable material. The practicality of each of these methods is highly dependable 
on the type of manufacturing method used to make the fibers. 
While both proteins and polysaccharides are useful natural biopolymers, the 
original research presented in this thesis focuses purely on protein materials, namely corn 
zein and Bombyx mori (B. mori) silk. In present literature, several distinct kinds of 
proteins and are used, including composite mixtures of proteins. Figure 1.1 illustrates 
these proteins and any workup required prior to dissolving them into solutions for 
biomaterial fabrication. The choice of protein varies with the desired material properties 
of the final biomaterial. Proteins are composed of amino acids, which form long chains of 
peptides to create the protein’s primary structure. Beyond that, various interactions with 
3 
itself, other proteins, or the environment including hydrogen bonding, disulfide bonding, 
London dispersion forces, charge-charge interactions, and dipole interactions shape the 
primary protein chain into higher-order structures like coils, helices, and sheets. Part of 




Preparation of Corn Zein and Bombyx Mori (B. Mori) Silk Solutions 
 
Note. B. Mori silk cocoons must be degummed by removing sericin prior to dissolution. 
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1.1.1 Silk 
Silk proteins are fibrous materials created by various arthropod species by 
spinning. The natural structure of these fibers is semi-crystalline, containing an ordered 
structure within a nebulous matrix 13. The protein structure of these silks varies greatly 
depending on the species of arthropod producing them; there are at present five different 
structures that have been identified. These structures include coiled coil, extended beta 
sheet, cross-beta sheet, collagen-like triple helix and polyglycine II 14-16. These 
differences are due to unique, specific amino acid sequences in the protein. As a result, 
various silks have various material properties including different mechanical strength, 
thermal integrity, bioactivity, chemical activity, and miscibility with other proteins. This 
versatility has been utilized to create several silk materials as thin protein films 17-19 and 
nanofibers 20-22 for a wide range of applications including targeted drug 23 and cytokine 
delivery 12, tissue engineering 20, 24, 25, and soft electronics 26-28. The mechanical strength 
of silk has lead to its long history in the textile industry, but recently the use of novel 
solvents 29, 30 and treatments 31, 32 have been utilized to tailor the beta sheet content of silk 
fibers in order to fine-tune its mechanical strength for a range of applications. 
1.1.2 Corn Zein 
Corn contains several proteins; zein is one of the major storage proteins, which 
makes it a very abundant source for biomaterials. Much of this comes from the 
bioethanol industry, where zein is a coproduct. In addition to its abundance, zein is also 
easily and cheaply extracted 33. Several different forms of corn zein exist in nature, 
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including alpha, beta, gamma, and delta zein 34. Similarly to silk, the properties of zein 
depend  on nanoscale structures and amino acid compositions 35. Studies have shown that 
zein is mostly composed of an alpha helical structure 35, but treatments and fabrication 
techniques can result in shifts in structure to random coils 8, 36 or beta sheets 37, 38. Zein 
also exhibits good biocompatibility, making it a promising candidate for biomaterials. In 
current research, zein is frequently used in tissue engineering 39, 40 and drug delivery 41. 
Zein can also be chemically modified to improve its mechanical properties 42, which 
helps overcome its limitations as its films tend to be brittle. Zein can also be turned into 
fibrous materials since it is thermally and chemically stable during the fiber spinning 
process; it produces the strongest fibers among vegetable proteins 43. 
1.1.3 Casein 
 Casein is a protein compromising roughly 80% of mammalian milk and is easily 
extracted, making it another widely available protein 44. It is a glycoprotein that form two 
disulfide bridges which help give casein a flexible external structure, as opposed to the 
set conformations that most proteins have 44. Because of this, casein tends to organize 
itself as micelles. In addition to a majority basic amino acid composition, casein also 
consists of four protein fractions- alpha 1, alpha 2, beta, and kappa 44, that contribute to 
its overall material properties. Casein is nontoxic and highly stable, which makes it a 
promising protein for use in biomaterials including drug delivery 45 and tissue 
engineering 46. From a biomedical perspective, casein is not a good candidate for fibrous 
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materials since it tends to form weak fibers 47, which makes it difficult to use in 
conventional methods in the literature such as electrospinning or solution spraying.  
1.1.4 Soy Proteins 
Soy extracts are another attractive protein for material applications. These are 
globular proteins which consist of two main units, conglycinin 7S and glycinin 11S. Both 
units are composed of primarily a random coil structure and contain subproteins of 
varying molecular weights. These units are either water-soluble albumins or globulins 
soluble in salt solutions, although most soy proteins are globulins 48. Soy protein isolates 
are attractive for functional biomaterials because they contain several functional groups 
that can interact with the surrounding environment. To date, soy proteins have been used 
for pollutant filtering 49, adhesives 48, and oxidation inhibition 50. Biomaterials is another 
major area of research for soy proteins, including tissue engineering 51, 52 and 
microencapsulation 53. The biggest downfall of soy-based materials is a lack of 
mechanical strength, which is often solved by creating soy composites with other 
polymers. This lack of mechanical strength is also the reason soy fiber materials are not 
possible without the addition of other polymers. 
1.1.5 Keratin 
Keratin, which is extracted from wool fibers, is another naturally derived protein 
commonly used for biomedical applications. Wool fiber keratin is often processed into 
nanofibers for various applications 54, 55, but other sources of keratin can provide keratin 
with different overall material properties. These other sources include horns, fingernails, 
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hair, and feathers. This results in several different types of keratin available in nature due 
to amino acid substitutions. For example a severe skin disease results from a substation of 
methionine amino acid with threonine in keratin 14 because a hydrophobic, nonpolar 
amino acid is substituted with a hydrophilic, polar amino acid 56. This disease damages 
the structural integrity of keratin that makes up the stratum corneum of the skin, 
highlighting how the integrity of keratin biomaterials is also heavily affected by amino 
acid sequences. This also applies to filtration applications, where natural keratin is used 
for the absorption of heavy metal ions due to its high amount of polar amino acids 55. The 
structure of keratin is distinct from other proteins in that it contains a high number of 
cysteine residues that form inter- and intra-molecular disulfide bonds, creating a compact 
3D structure that is resistant to chemicals 57. Keratin structure can further be 
distinguished into alpha and beta keratins. Alpha keratin, also called hard keratin, found 
in hair, wool, and nails, contains a higher sulfur content and consists of fibrils made up of 
intermediate filaments. Beta keratin, meanwhile, has a lower sulfur content and is found 
in birds, reptiles, and the stratum corneum of skin 57. The biocompatibility and strength of 
keratin make it a widely used natural biopolymer in biomedical research, including in 
tissue engineering 58, 59 and drug delivery 60, often using films or fibrous materials. 
1.1.6 Collagen 
Collagen is naturally found in over 29 different types. Its triplicate amino acid 
sequence enables collagen to form stable triple helices which can further develop into 
quaternary structures, giving rise to mechanically strong fibrils such as collagen V and XI 
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61. Collagen I, II, and III are also common fibril structures in the body, but every type of 
collagen provides unique signaling abilities in vivo for biomaterial applications 62. 
Dissolution of collagen partially destroys the triple helical structure, but allows it to 
regenerate into nanofibers 63. Nanofibers, films, and hydrogels are the most common 
biomaterials made from collagen, and collagen I is mainly used due to its abundance in 
nature 61. 
1.1.7 Elastin 
Another biomaterial protein that is a common native protein in vivo is elastin. 
Elastin is a critical protein component of the extracellular matrix (ECM) that provides 
elasticity in tissues and organs. It pairs with collagen, where collagen provides structure 
and mechanical strength, while elastin provides flexibility. Elastin is especially important 
in the lungs, aorta, and skin, where elasticity is crucial 64. Once again, amino acids play 
an important role in the structure and function of elastin just as with the other proteins 
discussed. By oxidizing lysine residues, elastin molecules uncoil to bind and crosslink 
other proteins and form elongated chains 65. Because of its elasticity and relationship to 
the ECM, elastin is a common protein used for vascular tissue engineering and blood-
interfacing biomaterials 66. Elastin is also used in other areas of tissue engineering 
including as a skin substitute 67. Most scaffolds using elastin, however, are combined 
with a material that is stronger mechanically like collagen. A popular topic in current 
research for elastin is self-folding proteins, where research has studied elastin’s self-
assembly into fibers, hydrogens, sheets, and more 68-72. 
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1.1.8 Reflectin 
First reported in 2004, reflectins are a relatively new class of proteins with unique 
spectral and optical properties, which allow self-assembly into reflecting materials 73. 
These proteins are found naturally in animals such as cephalopods and squids which use 
the special optical properties of reflectin for camouflage. A wide dynamic of structural 
colors is possible using reflectins due to a hierarchy of assembly at the nanoscale level 74. 
Current research into understanding this assembly hopes to design biomaterials with 
complex optical functions like active camouflage or contact lenses. Within conventional 
tissue engineering, reflectin has been used for neural tissue engineering to promote stem 
cell differentiation 75. Reflectin, too, is able to be processed into fibers through 
dissolution in organic solvents like conventional proteins 76. 
1.1.9 Composite Materials 
Most structural materials in biological systems are composites of 
biomacromolecules arranged in some hierarchy. The exoskeleton of arthropods, for 
example, is a dispersion of chitin within a matrix of silk-like proteins. Attempts to mimic 
this hierarchy behavior in biomaterials has shown that the physicochemical and 
morphological properties of the composite biomaterial (biocomposite) can be altered 
using natural materials such as silk, cellulose, and chitosan, or as a function of the 
fabrication method 77-79. Despite this research, it is still unclear how the hierarchy of 
biocomposite self-assembly dictates the secondary structures formed during biomaterial 
fabrication. Being able to predict the relationship between these hierarchies and the 
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overall physicochemical properties of a biomaterial would be a powerful tool. Along with 
this understanding, manipulating molecules to form structures with targeted size, spacing, 
and shape can create rapid fabrication of complex multi-level structures from a single 
biocomposite fabrication. Some biomaterials research has shown beta-sheet crystallites 
provide a network for crosslinking proteins to enhance their mechanical properties, but 
the morphology of the biomaterial is dependent on fabrication conditions and post-
fabrication treatments  80, 81. Understanding the mechanisms of molecular self-assembly 
will be essential to defining the natural nanoscale hierarchies that form powerful 
biocomposites in nature, and allow for the creation of powerful, fine-tuned biomaterials 
for a wide variety of applications. 
1.2 Project Motivation and Overview 
 All the above materials (biopolymers) are excellent candidates for drug delivery 
applications due to their biocompatibility, biodegradability, and tunable surface 
properties. Protein-based materials have long been an attractive alternative to synthetic 
materials for the production of plastic films19, 42, 82-91 and fibers8, 22, 30, 36, 43, 55, 82, 92-110 due 
to the availability of proteins, their ease of processing, and the tunability of protein-based 
material properties. The success of proteins used as drug delivery vehicles is a large part 
in this project’s motivation.8, 23, 36, 41, 51, 60, 70, 96, 111. We envision that proteins provide a 
cheap, easy, and biocompatible platform for a topical drug patch with tunable material 
properties to cater to a wide range of application sites and therapeutics. In addition, the 
substructures of proteins and the functional groups along their backbones provide an 
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additional means of controlling the release of therapeutics from the patch.8, 10, 36, 51, 70, 111, 
112 
 Today, drug delivery still faces several challenges from the patient level to the 
manufacturing level. For one, synthetic polymers are typically formed from petroleum 
byproducts or with harsh solvents that can harm the ecosystem. Even after production, 
most synthetic polymers are nonbiodegradable, which contributes to pollution after the 
product’s use. Biopolymers can be fabricated with less volatile solvents, some even 
recyclable,113 and are biodegradable products themselves, which helps combat pollution. 
Recycling and biodegradability make them more economic than synthetic polymers, 
which require constant replenishing and complicate disposal methods. 
 From the perspective of patients and healthcare professionals, drug delivery is 
also challenging. Patient compliance- ensuring patients take their intended dosage at the 
correct intervals- can be difficult. Therefore, this study tries to envision a simple patch 
that can be fine-tuned to control the release of various therapeutics at various rates. This 
patch would also reduce off-target effects. While topical drugs are applied to a local area 
on the skin, they still face issues from off-target effects from how far the therapeutic 
penetrates into the skin or staining of clothes that can be improved by incorporating them 
into a delivery vehicle.114  The protein-based patches developed in this study effectively 
integrate with the therapeutic molecules being delivered to improve the efficacy of their 




Zein-Based Thin Films and Air-Spun Nanofibers for the Topical Delivery of Sodium 
Citrate 
2.1 Introduction 
One of several complications of diabetes is ulcers on the foot. If left untreated, 
these wounds can lead to infections that lead to further complications, morbidity, or 
amputations.115, 116 While several treatment options exist, they only offer relief to a 
fraction of patients and come with undesired side effects.117 An alternative treatment that 
minimizes side effects and improves patient compliance utilizes citrus flavonoids 
delivered through a wound dressing.118 One such flavonoid, utilized in this study, is 
sodium citrate. Flavonoids promote healing through their anti-inflammatory, antioxidant, 
antiatherogenic, hepatoprotective, and neuroprotective properties. Citrate  is often used in 
drug delivery applications due to its ability to curate the immune response.119-121 In 
diabetic specifically, sodium citrate helps correct magnesium deficiency through its 
chelating properties.122 
The topical delivery of citrus flavonoids provides many benefits over other 
delivery routes including lower dose requirements and minimized off-target effects. 
Several different vehicles have been explored for drug delivery including micelles123, 124, 
liposomes125, 126, nanoparticles127, 128, nanofibers129, and thin films130. The use of these 
different vehicles allows for controlled, long-term release of topical drugs when placed 
on the skin to increase the efficacy of the treatment and the compliance of the patient. 
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Nanofibers and thin films in particular are typically easy to manufacture on a large scale, 
but maintain their specific targeting which improves efficacy and eliminates side 
effects130. Thin films create a bioavailable platform for rapid drug release, allow a fast 
onset of action and reducing the frequency of doses130. Nanofibers have also shown high 
promise for dermatological drug delivery due to their strong mechanical properties, low 
density, high porosity, and large surface area to volume ratio which provides a platform 
for enhanced drug loading131. 
Corn zein is a widely available protein, compromising roughly 80% of the total 
protein content found in corn and being a byproduct of bioethanol refinement93, 132-138. In 
biomedical and pharmaceutical applications, corn zein has been widely used by itself and 
in composite materials with some of the most successful applications using fiber and thin 
film materials139, 140. Much of the success of corn zein can be attributed to its good 
biocompatibility and biodegradability. These properties have resulted in its use in several 
topical drug delivery applications34, 111. Corn zein-based biomaterials also show 
antioxidative activity, which assists in wound healing and prevents damage to cells near 
the site of application141, 142. 
Biomaterials made from corn zein or composites of corn zein are flexible with 
high tensile strength, making them ideal for films11, 83, 143-145, nanofibers95, and 
composites146. Fabrication of nanofibers in particular is easy because zein is hydrophobic 
and insoluble in water. While electrospinning is one of the most common methods for 
nanofiber fabrication in current literature, it requires a high voltage source which limits 
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the overall efficiency of the process due to energy demands and dielectric constants147. 
To avoid these problems, air-jet spinning, also known as solution spraying, as utilized in 
this study. Air spinning utilizes compressed air and a concentric nozzle to stretch a 
polymer solution into fibers through high shear forces which cause the solvent to 
evaporate off, leaving behind polymer nanofibers that are deposited onto a collection 
surface148-150. This method of production is economical, simple to reproduce, and easily 
scales up to produce a large volume of nanofibers from polymer solutions with high 
efficiency. 
Within this study, corn zein was used to fabricate nanofibers and thin films 
incorporated with sodium citrate at different concentrations (1-30% wt drug/wt zein). 
These composite systems created a method for targeted, controlled delivery of sodium 
citrate to specific skin targets affected by diabetic ulcers112, 151, 152. Material 
characterization was done using FTIR, DSC, TGA, and SEM to understand the effects of 
sodium citrate on corn zein nanofibers and films. A cell biocompatibility study was also 
done to ensure biocompatibility after fabrication and after release of sodium citrate from 
the materials. Finally, a time-based drug release study quantified the release of sodium 
citrate from zein nanofibers and thin films and was used to understand the difference 
between 1D nanofiber geometry and 2D film geometry during drug delivery. The results 
suggested that nanofibers offer a better vehicle than films, since sodium citrate can 
interact with the secondary protein structure of zein nanofibers to shift them towards a 
more stable alpha-helical structure. After the citrate is released, however, the protein 
structure of zein nanofibers reverts to its original random coil structure. This reversible 
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transition, controlled transition showcases the potential for corn zein nanofibers to be 
used for the delivery of other topical drugs. 
2.2 Materials and Methods 
2.2.1 Preparation of Materials 
All materials obtained from companies were used without further modification. 
Corn zein powder of purity greater than 87% was obtained as a gift from POET, LLC. 
ACS Formic of 98% Grade was purchased from EMD Millipore Corporation and used as 
a solvent. For samples containing drug, sodium citrate tribasic dihydrate with greater than 
99% purity for molecular biology from Sigma-Aldrich was used. 
2.2.2 Corn Zein Nanofibers 
 Corn zein solutions were first created by dissolving 5.3 g of corn zein in 10 mL of 
formic acid. Homogenization was ensured using a benchtop vortexer. In samples 
containing 1%, 5%, 10%, 15%, 20%, or 30% (wt drug/wt zein) sodium citrate was 
dissolved in formic acid prior to adding corn zein. Once fully dissolved and 
homogeneous, the solutions were transferred to a disposable syringe to attach it to a 
siphon-feed airbrush. An air compressor provided 100 psi of pressure to the airbrush in 
order to shear the solution into nanofibers. Nanofibers were collected into an aluminum 
foil lined box a distance of 1.5 m away from the airbrush. Collected nanofibers were 
dried in a vacuum oven at 60 °C overnight to evaporate excess formic acid prior to any 
characterization. 
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2.2.3 Corn Zein Films 
 Corn zein films were also fabricated to compare the effects of 1D nanofiber 
geometry to 2D thin film geometry for drug delivery applications. The protein solution 
for films were prepared the same way as the solutions for nanofibers above. Instead of 
using an airbrush, 2 mL of each sodium citrate-zein solution was casted onto a PDMS 
mold for each wt% of citrate. Casted solutions dried at room temperature for 2 days, 
followed by removal of excess formic acid in a vacuum oven at 60 °C overnight. The 
final thickness of the films measured around 20 µm. 
2.2.4 Scanning Electron Microscopy (SEM) 
 Scanning Electron Microscopy (SEM) was used to measure the surface 
morphology of fiber and film samples using a LEO 1530 VP SEM at an EHT of 10 kV. 
Prior to imaging, samples were sputter coated with gold for 15 s. 
2.2.5 Fourier Transform Infrared Spectroscopy (FTIR) 
 For further morphology analysis, Fourier Transform Infrared Spectroscopy 
(FTIR) was performed on samples with a Bruker Tensor 26 Fourier Transform Infrared 
Spectrometer equipped with deuterated triglycine sulfate detector under nitrogen purge 
gas at 50 mL/min. Spectra was obtained from 4000 to 400 cm-1 with 64 scans at 4 cm-1 
interval resolution using a multiple reflection, horizontal MIRacle ATR attachment. To 
ensure homogeneity, all samples were measured at least once on both sides. Between 
samples, the ATR crystal was cleaned with alcohol and 64 background scans were taken. 
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2.2.6 Differential Scanning Calorimetry (DSC) 
 To analyze the thermal stability and miscibility of the composites, temperature 
modulated differential scanning calorimetry (TM-DSC) was performed using a Q100 
DSC outfitted with a refrigerated cooling system (RCS). Before use, the instrument was 
calibrated against indium standards for heat flow and temperature and with aluminum and 
sapphire standards for heating capacity. 5 mg of each sample was enclosed into 
aluminum pans and analyzed from -40 to 400 °C at a heating rate of 20 °C/min, 
temperature amplitude of 0.318 °C, and modulation period of 60 s. Nitrogen purge gas at 
50 mL/min was used to prevent oxidation. 
2.2.7 Thermal Gravitational Analysis (TGA) 
Further thermal analysis was performed by thermal gravitational analysis (TGA) 
using an SDT-Q600 instrument. The mass of samples was recorded over a 25-800 °C 
range at a constant rate of 10 °C/in while under nitrogen purge gas at 100 mL/min. The 
starting mass of all samples was 5 mg. 
2.2.8 Drug Release Study 
Samples of select citrate concentrations (5%, 10%, 20%, 30% wt drug/wt zein) 
were prepared in sets of five along with triplicate samples of 0% zein nanofibers. 0% 
nanofibers were used as error bars to account for mass lost due to fiber degradation; all 
samples measured about 6 mg. All samples soaked in 200 μL of deionized water over a 
72 h time period. At designated times (0.25, 0.5, 1, 2, 3, 4, 5, 6, 12, 24, 36, 48, 60, 72 h) 
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samples were moved to a new, clean well with 200 μL of deionized water. Parafilm was 
used to cover the wells between measurement times to prevent contamination or loss of 
water. To measure the amount of drug released into each water well, the solutions were 
run through pre-weighed filter paper and then excess water was dried off in a vacuum 
oven. The filter paper was then re-weighed to record the amount of drug released at that 
time point. The sum of each of these mass points was recorded to plot a cumulative drug 
release plot for each set of citrate weight percentage using the  average of the five 
samples. At the end of the study, the remainder of the samples was dried in a fume hood 
for 4 days and their final mass was recorded. 
2.2.9 Statistical Analysis 
To compare the release of citrate between fibers and films, a paired two-sample t-
test was performed using Excel. A null hypothesis was proposed that the mean amount of 
drug released from fibers was the same as the mean amount of drug released from the 
films. Each pair of samples (fibers and films) for each wt% (1%, 10%, 20%, 30 wt%) was 
tested separately. 11 time points were recorded, giving the test 10 degrees of freedom. An 
5% significance level was chosen, giving a two-tailed alpha level of 0.05. To test for 
covariance, the Pearson correlation coefficient was also calculated between each wt% 




2.2.10 Biocompatibility Study 
To confirm the biocompatibility of the samples, HEK293 (human embryonic 
kidney) were grown of samples using Dulbecco’s modified Eagle’s medium 
supplemented with 10% fetal bovine serum (FBS) and 100 U/mL Penicillin-
Streptomycin. Culturing conditions were in an atmosphere of 95% air and 5% carbon 
dioxide at 37 °C according to NIH standards. Samples were first sterilized under UV light 
overnight, then an equal amount of cells were seeded on both fiber mats and thin films. 
Cells were also seated on a blank petri dish was used as a control. After 72 h of culturing, 
a 3-[4,5-dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay was used 
to quantify cell viability. 
2.3 Results and Discussion 
2.3.1 Structural Characterization 
To begin understanding the interactions of sodium citrate with the structure of 
corn zein, FTIR was first used. A comparison was performed between corn zein fibers 
and thin protein films with varied weight percentages of sodium citrate (0%, 1%, 5%, 
10%, 15%, and 30%). The full absorbance spectra of zein fiber samples is showed in 
Figure 2.1a with Figure 2.1b showcasing the changes in secondary protein structure in the 
Amide I and II regions. Within the Amide I region, corn zein without any citrate shows 
an absorption peak at 1650 cm-1 which indicates a random coil network. 153-155. After 
sodium citrate is added, all embedded samples see a shift in the absorbance peak to 1650 
cm-1 which represents an alpha-helical protein structure. This analysis indicates that in 
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1D fibers, zein protein interacts with sodium citrate through hydrogen bonds or charge-
charge interactions to shift the protein from a random coil network towards a more 
orderly structure. In the Amide II region (Figure 2.1a), this interaction is further 
supported by shifts in absorbance in the region associate with the protein side chain. 
Specifically, pure zein shows a peak at 1531 cm-1 which shifts to 1538 cm-1 in citrate-
loaded fibers due to the denser alpha helices pushing more zein side chains to become 
exposed on the protein backbone. 
 
Figure 2.1  
FTIR Absorbance Spectra for Corn Zein Nanofibers 
 
Note. (a) Full FTIR spectra. (b) Amide I and II Regions of Fibers. Unloaded fibers show 
a peak at 1640 cm−1 indicative of random helical structure while fibers loaded with 
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sodium citrate show a shift to alpha helical structure at 1650 cm−1. All samples with 
citrate show shoulder at 1720 cm−1 that scales with wt% of citrate. 
 
Thin films do not show the same interaction with sodium citrate that the 
nanofibers do. The full FTIR spectra of the zein films is shown in Figure 2.2a, with the 
Amide I and II regions highlighted in Figure 2.2b. Zein films without citrate contain a 
peak at 1647 cm-1 which indicates an alpha-helix dominated structure156. The addition of 
citrate does not produce any clear trends, but does decrease the shoulder at 1638 cm-1 
which corresponds to a decrease in random coil structure. This behavior is also related to 
zein’s inherent tendency to decrease in alpha helical structure after exposure to 
solvents38. Thin films see the introduction of a peak unique to the films at 1386 cm-1 
which is often associated with symmetric -COO bond stretching157. This peak is likely 
caused by residual formic acid trapped inside of the 2D films due to the nature of film 
fabrication. Where residual formic acid is mostly evaporated during nanofiber fabrication 
because of the shear forces with the remainder removed during drying, film fabrication 




FTIR Absorbance Spectra for Corn Zein Films 
 
Note. (a) Full FTIR spectra. (b) Amide I and II regions for films. Unlike the nanofibers, 
there is an insignificant shift in absorbance peak when sodium citrate drug is embedded. 
Like in the fibers, all samples with citrate show shoulder at 1720 cm−1 that scales with 
wt% of citrate. 
 
Both fiber and film samples with sodium citrate see a shoulder at 1710 cm−1 that 
scales in intensity with an increase in wt% of sodium citrate. Accordingly, fibers and 
films without sodium citrate lack this peak (Figure 2.1b and Figure 2.2b). All samples 
also see a shoulder at 1710 cm-1 as a result of C=O bond stretching caused by hydrogen 
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bonding between protein side chains and sodium citrate molecules158. Further evidence of 
side chain interactions is also evident in the peak at 1572 cm-1 in citrate-embedded 
samples. This argument is made based on previous literature indicating that this peak is 
caused by asymmetric stretching of -COO bonds157. There is also a broad peak in all 
samples in the 2000-1800 cm-1 region commonly associated with the presence of water. 
2.3.2 Thermal Analysis by DSC 
Thermal analysis was first performed using temperature modulated differential 
scanning calorimetry (TM-DSC) on corn zein nanofibers embedded with sodium citrate. 
Two key temperatures (Table 2.1) were extracted from all samples based on the 
thermogram in Figure 2.3a. These are Tw, related to the evaporation of water embedded 
in the samples, and Td, related to degradation of the bulk samples themselves. All 
samples are stable well above physiological conditions, rendering them safe for the 
delivery of various therapeutics and for transportation or storage in hot climates.  
TM-DSC was also used to see changes in reversing heat capacity in the samples 
(Figure 2.3b). The zein-citrate composite fiber samples all showed two glass transition 
temperatures (Tg), although the lower Tg is much broader at lower wt% of citrate and 
becomes more defined at higher wt%. This trend indicates that the lower Tg is related to 
citrate-zein interactions. The higher Tg is much more defined in all samples. This, 
coupled with their correlation to the thermograms produced by thermal gravimetric 
analysis (TGA), indicate that this Tg is related to the breakdown of the bulk composite 
material. Past this higher Tg, the composites begin to break down (Figure 2.3b). Since the 
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corn zein-citrate nanofiber composites have a high initial Tg (>100 °C) and a narrow step 
in heat capacity, this analysis implies that the nanofibers are ideal drug delivery vehicles 
for sodium citrate due to strong interactions that form a thermally stable structure. 
 
Figure 2.3 
DSC Thermograms of Sodium Citrate-Zein Nanofibers 
 
Note. (a) Heat flow changes at Tw due to water evaporation and Td due to thermal 
degradation. (b) Step changes in reversing heat capacity can be found at Tg1 and Tg2 for 





Critical Temperatures Extracted from DSC Analysis on Sodium Citrate Embedded Corn 
Zein Nanofibers 
Citrate wt% Tw (℃) Td (℃) Tg1 (℃) Tg2 (℃) 
1 81 311 139 N/A 
5 83 305 128 189 
10 73 297 104 190 
15 78 297 109 188 
20 75 290 116 187 
30 69 289 105 186 
 
A parallel DSC analysis was also performed on corn zein protein films embedded 
with sodium citrate. Due to the thermally unstable nature of these composites, there is 
less numerical data to extract from this analysis. Regardless, a visible trend can still be 
seen in the thermogram in Figure 2.4a. With higher percentages of citrate, the composite 
films see less degradation, which implies that sodium citrate still helps to stabilize the 
thin films despite lacking the strong interactions seen in the nanofiber composites based 
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on FTIR analysis. This lack of interactions causes all film composite samples to degrade 
earlier than the nanofiber composites; nanofiber samples do not begin degrading until at 
least 250 °C, but films show major degradation by 220 °C. Even analyzing the reversing 
heat capacity (Figure 2.4b) of the film composites, the only trend that can be seen is a 
reduction in noise with an increase in wt% of sodium citrate. Regardless, all films still 
begin degradation around 150 °C. 
 
Figure 2.4 
DSC Thermograms of Sodium Citrate-Zein Films 
 
Note. (a) Heat flow thermogram of zein-citrate composite films. Degradation begins 
earlier than in nanofiber composites. (b) Reversing heat capacity thermogram shows 
noise due to the thermal instability of the composites beginning at 150 °C. 
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2.3.3 Thermal Gravimetric Analysis (TGA) 
The results from DSC analysis were further cross-checked using TGA. Nanofiber 
composites were first analyzed and compared to the Tw and Tg found from DSC. The 
thermogram produced (Figure 3.5a) shows sharp decreases in sample weight at 
temperatures corresponding well to the Tw and Tg values found during DSC analysis. The 
derivative of mass loss shown in Figure 3.5b demonstrates the superior thermal stability 
of the nanofiber composites. The initial change in mass around 50 °C correlates to Tw. 
This peak shifts to lower temperatures in samples containing a higher wt% of citrate due 
to higher bound water content. Most of the mass loss in the samples occurs in the 300-
350 °C region, which correlates to the Td found during DSC analysis as temperatures 




TGA Thermograms of Sodium Citrate-Zein Nanofibers 
 
Note. (a) Weight fraction of zein-citrate nanofibers up to 800 °C. (b) First derivative of 
the remaining mass helps visualize two peaks due to bound water evaporation and zein 
degradation. 
 
A similar analysis was also performed on corn zein sodium citrate composite 
films using TGA. Similar to the DSC results, TGA confirmed that film composites are 
less thermally stable than their nanofiber counterparts. All samples show a large amount 
of degradation, although samples with higher amounts of citrate resist degradation 
slightly better (Figure 2.6a). The thermal instability of protein films is further shown 
through the differential thermogram in Figure 2.6b, where several small peaks are visible 
between 100-250 °C due to noise. Another parallel to the DSC analysis is the lack of a 
degradation peak related to water evaporation. There is also good correlation between the 
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TGA thermogram in Figure 2.4b and the DSC thermogram in 2.6b in that both show 
major degradation of the zein film composites beginning around 150 °C. The TGA 
analysis does show that sodium citrate may interact with protein films in some way to 
help stabilize them at high weight percentages of citrate, but this interaction is not 
comparable to that in the nanofibers as evident by their lower onset of degradation and 
the lack of changes in protein structure (FTIR analysis). Thus, despite film composites 
maintaining a higher weight percentage overall, nanofiber composites still hold stronger 
thermal integrity over a higher temperature range. 
 
Figure 2.6 
TGA Thermograms of Sodium Citrate-Zein Films 
 
Note. Weight fraction of zein-citrate films up to 800 °C. Samples retain a higher mass 
overall but degrade much earlier than nanofibers. (b) First derivative of the remaining 
mass. The large presence of noise indicates thermal instability. 
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2.3.4 Morphology Analysis 
 Given the results of the structural and thermal analysis given above, it was 
decided that corn zein film composites were not suitable for long-term biomedical 
applications. Because of this, the remainder of this study focused exclusively on the use 
of nanofibers for biomedical applications including drug delivery. Scanning electron 
microscopy (SEM) was performed on several nanofiber samples of varying wt% of 
embedded citrate to study its effects on the nanofiber mesh morphology. The results 
showed that at lower wt% of citrate (>=10%), the composite samples can maintain their 
desirable nanofiber properties (Figure 2.7a-c). Specifically, the nanofibers maintain 
nanoscale diameters and the fiber network stays porous, which allows for cell infiltration 
and the transport of embedded drugs. The nanofibers also maintain a high surface area-to-
volume ratio, which benefits many applications of fibrous materials8, 96, 129, 131, 159, 160. 
Some small droplets of sodium citrate are still visible in these images, but the overall 
morphology of the nanofiber network is mostly unaffected. When compared to higher 
wt% of sodium citrate (15-30 wt%) (Figure 2.7d-f) the fibers become saturated with 
citrate and form large globules that deteriorate the benefits of a nanofibrous mat. In these 
samples, the fibers lose their nanoscale diameters and the globules of citrate cause the 




SEM Images of Sodium Citrate Embedded Zein Nanofibers 
 
Note. Sodium citrate varies from 1 to 30 wt% citrate/zein: (a) 1 wt%, (b) 5 wt%, (c) 10 
wt%, (d) 15 wt%, (e) 20 wt%, and (f) 30 wt% sodium citrate embedded nanofibers. (scale 
bar size: 10 µm). 
 
2.3.5 Drug Release Profile 
 The release of sodium citrate from corn zein nanofibers and thin films was 
compared by plotting the cumulative mass released from both samples over a 72-h time 
period. The mass of citrate released from each set of samples was averaged and 
normalized to 100% released at 72-h. Error bars were added to the thin film plot in Figure 
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2.8a based on standard deviation and to the fiber plot in Figure 2.8b based on the average 
mass lost to degradation of pure zein fibers in water. 
 
Figure 2.8 
Release Profiles of Sodium Citrate from Corn Zein Nanofibers and Thin Films 
 
Note. Normalized release profiles of sodium citrate from corn zein films (a) and fibers 
(b). Content of sodium citrate ranged 5 to 30 wt% drug/zein with samples taken between 
0.25–72 h. 
 
 In both the film and the fiber samples, most of the embedded sodium citrate is 
released in the first 6 h of soaking. There is a biphasic release in all samples, but fiber 
samples plateau at a lower percentage (45-60%) than films do (60-75%). From 52-72 h, 
the remainder of the citrate is released from the samples. During the initial release, before 
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the plateau period, corn zein films release citrate slower than the nanofibers due. Beyond 
the plateau, the reverse becomes true; films release citrate faster than nanofibers from 52-
72h h. This is likely caused by charge-charge or hydrogen bonding interactions between 
the citrate molecules themselves since the molecules contain an alcohol and several 
carbonyl groups. Once a majority of the citrate has been released (>75%), citrate 
molecules are less prevalent for self-interaction, which leads to faster release and 
dissolution. This trend is most obvious with the 30 wt% citrate films (Figure 2.8a, pink 
triangles). 
 Fiber samples generally have a slower, more controlled release of citrate as 
indicated by their lower plateau. This is expected and reported in several other drug 
release studies due to the large surface area-to-volume ratio that nanofibers provide8, 129, 
159, 160. This controlled release is also caused by the molecular interactions seen in the 
FTIR analysis, where citrate molecules interact with the protein structure of zein in 
nanofibers, but not in films. 
 To provide a quantitative comparison of citrate release between fibers and films, a 
paired two-sample t-test was performed for each wt% of citrate using Excel. The results 
are summarized in Table 2.2. All test results were compared to a T-critical of 1.812 at a 
0.05 alpha significance level. With T-statistics of 3.948, 3.363, and 4.128 for 5, 10, and 
20 wt% citrate being higher than the T-critical of 1.812, the null hypothesis for these 
groups was rejected. 30 wt% citrate had a T-statistic of 1.464, so the null hypothesis was 
accepted. Within this study, the null hypothesis was that there was no significant 
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difference in the mean mass of citrate released by films and fibers. Therefore, only the 30 
wt% nanofibers had a statistically comparable drug release to their film counterparts. 
This was further supported by the calculated p values. Once again, 5, 10 and 20 wt% 
samples were determined to be significantly different with p values of 0.003, 0.007, and 
0.002, respectively. For the 30 wt% group, a p value of 0.174 was calculated, indicating 
again that there was no significantly different release of citrate between the fibers and the 
films. Comparing these results to the morphology analysis makes sense; at 30 wt% 
citrate, nanofibers lost their porous characteristics and became brittle, likening them to 
thin films rather than the porous nanofiber networks seen in the lower wt% samples. All 





Statistical Comparison of Citrate Release from Zein Nanofibers and Thin Films 
Citrate wt% Pearson 
Correlation 
T-Statistic p (T≤t) 
5% 0.983 3.948 0.003 
10% 0.977 3.363 0.007 
20% 0.984 4.128 0.002 
30% 0.993 1.464 0.174 
Note. Summary of important statistics obtained from a paired two sample t-test between 
the average mass of citrate released from fiber and film samples at each citrate wt%. All 
samples were analyzed with an alpha level of 0.05 and a t-critical of 1.812. 
 
2.3.6 Cell Compatibility and Effect of Sodium Citrate Release 
 To demonstrate the potential of zein nanofibers for topical drug delivery, cell 
biocompatibility studies were performed using human embryonic kidney cells (HEK293). 
Cells were cultured on zein fibrous mats embedded with 0-30 wt% sodium citrate for 72 
h. Cells were also cultured on a plastic petri dish as a control. After 72 h, light 
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microscopy was used to study the morphology of the cells on the materials (Figure 2.9). 
The morphology on the zein materials was comparable to that of the control. 
 
Figure 2.9 
Light Microscopy of HEK293 Cells on Zein-Citrate Fibrous Mats 
 
Note. Cell morphology on zein fibrous mats is comparable to that of the control. 
 
Following microscopy, the metabolic activity of the cells was evaluated using an 
MTT assay (Figure 2.10). When compared with the control, zein fibrous materials 
showed a significantly increased metabolism, indicating enhanced proliferation of cells 
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on the zein fibers. It was also seen that at lower concentrations of sodium citrate (<15%) 
there was an increase in metabolism compared to zein without sodium citrate, indicating 
that the addition of citrate could improve the health of cells in biomedical applications. 
At higher amounts of citrate, however (>15%), the metabolic activity of the cells 
becomes lower. This could indicate that the release of sodium citrate in the materials 
inhibits cell proliferation, although it could also be a result of the change in fiber 
morphology at these higher amounts of citrate as seen in the SEM analysis. The increase 
in fiber diameter and decrease in porosity at these higher amounts of citrate limits the 
transport of sodium citrate through the material and reduces drug-cell interactions. 
Significant differences in cell metabolism was confirmed by T-Test between sample 




MTT Assay of 72-h HEK293 Cell Culture on Zein-Citrate Fibrous Mats 
 
Note. HEK293 (Human embryonic kidney) cells cultured on zein fibrous mats for 72 h 
showed improved metabolic activity compared to a control petri dish. T-tests were 





To study the effects of the release of sodium citrate from the materials on the zein 
protein structure, embedded nanofibers were analyzed by FTIR again after soaking in 
PBS for 72 h (Figure 2.11). Upon release of sodium citrate, zein nanofibers revert back to 
their original random coil structure indicated by the absorbance peak at 1640 cm-1. In 
addition, the peak at 1720 cm-1 caused by C=O stretching between the zein protein chains 
and sodium citrate molecules disappears, further confirming the interaction inferred in the 
initial FTIR analysis. This makes zein protein an ideal candidate for drug delivery 
applications, since therapeutic molecules cause stabilizing interactions, but do not 




FTIR Analysis on Zein Nanofibers after Citrate Release
 
Note. Absorbance in the Amide I region in all zein fiber samples reverts to the 1640 cm-1 
seen in zein fibers without citrate. This indicates a reversible transition back to the 
original random coil structure of zein before citrate was embedded. 
 
2.3.7 Mechanism 
The increased thermal stability of zein nanofibers compared to zein films is likely 
due to stabilizing interactions between sodium citrate and zein protein in the nanofibers. 
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As seen in the Amide I and II regions of the FTIR spectra, citrate-embedded fibers shift 
their protein structure from a random coil network towards an alpha helical conformation. 
Since alpha helices are stabilized by hydrogen bonding, it is plausible that the same 
interaction between citrate molecules and the zein protein structure that causes a shift in 
protein structure is also responsible for the higher degradation temperature of the fibers. 
This interaction was not seen in the films, which degrade at lower temperatures than the 
fibers. Thermal analysis was also able to confirm that in samples with more citrate, there 
is a reduction in degradation. This is seen as a more gradual change in mass in the TGA 
thermograms and sharper changes in reversing heat capacity in the DSC thermograms. 
Embedded zein films do not see these same properties because of the lack of interaction 
between sodium citrate and the zein protein structure. Despite hydrogen bonding between 
sodium citrate and the protein structure in zein fibers, the change in protein conformation 
is reversible upon release of citrate. This makes zein protein a useful candidate for drug 
delivery applications, since therapeutic molecules can interact with the protein structure 
to stabilize the composite without permanently altering the structure of the protein 





Mechanism of Interaction 
 
Note. Sodium citrate is embedded into 1D zein fibers or 2D zein films. 1D zein fibers 
have higher thermal stability and promote cell biocompatibility. 
 
2.4 Conclusions 
Corn zein fibrous nanofibers proved to be an effective carrier for sodium citrate, 
which can be delivered topically as a patch to treat diabetic ulcers. Analysis of the zein 
protein structure through FTIR showed that sodium citrate can interact with zein to shift 
its protein structure from an unstable random coil to a stabilized alpha helical network. 
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The same interaction was not seen in corn zein films. This interaction resulted in a 
slower, more controlled release of sodium citrate from the nanofibers compared to the 
films, but did not permanently alter the protein structure. Upon release of citrate, zein 
nanofibers reverted back to their original random coil structure. At the same time, the 
alpha helical structure induced by sodium citrate improved the thermal stability of corn 
zein fibers, resulting in a higher degradation temperature than their film counterparts. 
This thermal stability was confirmed by DSC and TGA analysis. Despite this, there is a 
limit to sodium citrate content exists where nanofibers begin to lose their porosity and 
nanoscale diameter, which limits their usefulness as a drug delivery carrier and the ability 
of cells to proliferate in the fiber network. SEM morphology analysis as well as 
biocompatibility studies confirm this. Because of this, a lower concentration of sodium 
citrate (5~15%) may be more suitable for biomedical applications. Despite this limitation, 
zein nanofibers still show promise with the potential to be used for the delivery of other 
therapeutic molecules. The unique tunability of biomaterials provide many means of 
modifying the physicochemical properties of the material to cater to specific applications 
as needed to accompany different therapies and patients. We envision the combination of 
these corn zein mats with sensors to detect swelling which will alert patients or providers 




Study of Silk-Based Thin Films and Air-Spun Nanofibers for Topical Drug Delivery 
Using Various Model Drugs 
3.1 Introduction 
 An emerging field of research aiming to solve many of the current problems with 
drug delivery is protein-based drug delivery vehicles 136. Very frequently, protein 
biomaterials in the form of nanofibers 8, 9, 23, 111, 112, 131, 136, 161  or thin films 8, 9, 23, 111, 130, 136 
are fabricated to delivery therapeutics. These types of delivery vehicles provide many 
benefits over systemic delivery, mostly by reducing off-target effects and lowering 
dosage requirements to improve patient compliance 136, 162. This study places particular 
interest on nanofibers due to their high surface-area-to-volume ratio and high porosity, 
which improve drug loading efficiency and enhance mass transfer properties 8, 36, 97, 161, 
163. Because of their protein origin, protein-based nanofibers provide additional 
biocompatibility, biodegradability, and bioactivity due to differing protein structures and 
amino acid sequences that allow biochemical and biophysical interactions with 
therapeutics 55, 164. Today, protein-based nanofibers are limited in clinical use due to a 
lack of quantitative data and the need for a reliable large-scale production method 165. 
 One solution for the plausible scale-up production of nanofibers is through air-
spraying or solution blowing. To date, the most common nanofiber fabrication methods 
are electrospinning and techniques directly related to it 94, 166-169. Electrospinning works 
by connecting the outlet of a spinneret to a high voltage power source. When surface 
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tension in the polymer solution is overcome by electrostatic forces, the polymer is drawn 
into fibers to be collected on a grounded surface or a collection bath 170. The need for a 
high voltage power source makes this method costly and dangerous, and the throughput is 
slow. This study utilized an alternative fiber fabrication technique known as air-spraying 
or solution spraying. Instead of high voltage, this method uses compressed air as the main 
driving force of fiber formation 8, 36, 108, 150. A concentric nozzle is used where one inlet is 
fed polymer solution and the other is fed high pressure air from a compressor; the high-
pressured air shears the polymer solution into strands of fibers, which quickly form solid 
fibers once the solution leaves the nozzle and the solvent evaporates off. The fibers can 
be collected on a range of substrates similar to electrospinning, but the process has a 
higher throughput 108 which makes it a potential method for large-scale nanofiber 
production. 
 Protein-based nanofibers can be made from a wide variety of proteins 20, 55, 95, 105, 
164, but this study chose to use Bombyx mori silk specifically due to its mechanical and 
thermal properties, chemical stability, and good biocompatibility 87. In nature, silk 
cocoons consist of two major components: silk fibroin protein and sticky sericin proteins. 
By boiling the cocoons in weak saltwater, one can separate the silk fibroin to produce silk 
biomaterials in several different forms 10, 31, 90, 103, 154, 168, 171, 172. Depending on the source, 
silk can contain slightly differing protein structures due to differing amino acid 
structures. Bombyx mori silk owes its strong mechanical properties to intermolecular beta 
sheets that form due to the amino acid sequence 173. These beta sheets also enhance the 
bioactivity of silk, allowing for tunable properties by tailoring the beta sheet content in 
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the silk to change its mechanical properties or tailor the release of drugs from the 
biomaterial structure 32, 174. 
 Several studies (cited above) have focused on the use of silk films for controlled 
drug delivery, but little research has been done using silk nanofibers for the same 
purpose. The strong mass transfer benefits of nanofibers, coupled with the ability to tailor 
crystallinity (beta sheets) in silk, provide a promising platform for the controlled release 
of therapeutic molecules. Within this study, the porous 1D geometry of silk nanofibers 
was compared to the flat 2D geometry of silk films with respect to the release profile of 
several model drugs. These models varied in weight, charge, water solubility, and 
hydrophobicity, and were chosen to reflect the type of drugs used in the market today. 
FTIR, SEM, TGA, and DSC were all used to study the effects the model drugs had on the 
protein structure of silk biomaterials and their subsequent release from the biomaterials. 
The release profiles of the model drugs were also studied in order to compare the effects 
of biomaterial geometry on release speeds. 
3.2 Materials and Methods 
3.2.1 Materials Preparation 
Silk cocoons from the Bombyx mori silkworm were purchased from Treenway 
Silks. Prior to use, the silk fibroin protein was separated from the sticky sericin proteins 
by boiling cocoons in a 0.02 M NaHCO3 (Sigma-Aldrich) solution for 15 minutes. Silk 
fibroin fibers were then washed in deionized water for 15 minutes, four times, and dried 
in an oven at 60 ℃ overnight. To dissolve silk fibroin, a solution of 4% wt./vol CaCl2 
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was prepared using CaCl2 from AMRESCO and 98% grade ACS purity formic acid from 
EMD Millipore. Crystal violet, indigo carmine, alcian blue 8GX, rhodamine B, and 
rifampin (rifampicin) were used as-is from VWR International. 
3.2.2 Silk Nanofibers 
 Oven-dried (60 ℃) silk fibroin fibers were used to fabricate silk nanofibers. 0.75 
g of silk fibers was dissolved into 5 mL of 4% CaCl2 formic acid solution based on prior 
studies 154. At this concentration, silk nanofibers maintain the high mechanical strength 
and thermal stability of silk, but the concentration is low enough to prevent clogging of 
the spray gun. For model drug-embedded silk fibers, 0.05 g (1% wt./vol) was dissolved in 
CaCl2 formic acid before adding silk. To facilitate dissolution, a benchtop vortexer was 
used, following by centrifugation at 2000 RCF for 10 minutes. Once the solution was 
homogeneous and free of aggregates, the solution was transferred to a Leur-Lok syringe 
to be sprayed through a high-pressure low volume (HPLV) gravity-feed spray gun. The 
spray gun was fed ultra-dry air at 80 psi to shear the solution into fibers which were 
collected on a grated substrate roughly 20 cm away from the nozzle. Fine-tuning of the 
air pressure, spray angle, and fluid intake was controlled via knobs on the spray gun to 
optimize fiber formation. In most situations, the smallest spray angle, lower fluid intake, 
and lower pressure was optimal. The relative humidity in the environment varied from 
20-22% during fabrication. All fibers were collected from the substrate immediately after 
spraying and transferred to storage in a vacuum oven at 60 ℃ overnight (12+ hours) to 
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remove any excess CaCl2 formic acid solution that did not evaporate during air spraying. 
Figure 3.1 (top path) below illustrates the process. 
 
Figure 3.1 
Silk Biomaterial Synthesis 
 
Note. Silk-model drug solutions were spun into nanofibers via spray gun or casted onto 
PDMS molds for film fabrication. 
 
The choice of model drugs in this study were chosen based on the library of 
pharmaceutical compounds in the pharmacopeia. They represent a varying set of 
physicochemical properties including in their molecular weight, solubility, charge, and 
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hydrophobicity (Table 3.1). All model drugs had distinct, measurable absorbance within 
the UV-visible light spectrum, proving a reliable quantification assay for measuring their 
release from the biomaterials. A very small amount of the drug was detectable, which 
helped to prevent model drug crystals from clogging the spray gun.  
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Table 3.1 










407.98 50 1.4 
Indigo carmine 
 
466.36 10 1.01 
Rhodamine B 
 
497.02 9 1.95 
Rifampin 
 
822.94 2.5 2.77 
Alcian blue 
 
1298.9 1 -9.7 
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3.2.3 Silk Films 
 To compare the effects of biomaterial structure and morphology on release 
kinetics, 2D silk films were also fabricated and embedded with model drugs. Silk 
solutions were prepared in the same way as they were prepared for fibers, but only 3 mL 
of the solution was cast onto circular PDMS molds for film fabrication (Figure 3.1, 
bottom path). Solutions plasticized at room temperature for 48 h to allow films to form; 
drying in a vacuum oven at 60 ℃ for 12 h after film formation assisted in evaporating 
excess solvent before any characterization tests were performed. 
3.2.4 Morphology Characterization 
Characterization of the silk biomaterial morphology was performed using 
Scanning Electron Microscopy (SEM) imagery from a Zeiss Leo 1530 VP SEM. Samples 
were sputter coated in gold to improve their conductivity, followed by imagine at 100, 
500, 1000, 2000, and 5000x at an EHT of 5.00 kV. Not all images are displayed in this 
thesis. ImageJ image processing software was used to measure the average diameter of 
the fiber samples to study the effects of drug loading on fiber morphology as well as the 
general size of fibers produced by air spraying. 
3.2.5 Fourier Transform Infrared Spectrometry (FTIR) 
 Additional morphology analysis was performed by using Fourier Transform 
Infrared Spectroscopy (FTIR) to study the protein structure in the biomaterials. A Bruker 
Tensor 27 Fourier Transform Infrared Spectrometer with deuterated triglycine sulfate 
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detector and multiple reflection horizontal MIRacle Attenuated Total Reflection (ATR) 
attachment, fitted with a Ge crystal, was used to obtain the spectra. Readings were taken 
from 4000 to 400 cm-1 with a resolution of 4 cm-1. All samples were read with 64 samples 
scans and 64 background scans, and readings were taken at least twice on each side to 
ensure homogeneity throughout the sample. Between different samples, the ATR crystal 
was cleaned with methanol.  
3.2.6 Differential Scanning Calorimetry (DSC) 
Thermal analysis was first performed using Temperature-modulated Differential 
Scanning Calorimetry (TM-DSC) with a Q100 DSC from TA Instruments. The 
instrument was equipped with a refrigerated cooling system and purged with nitrogen gas 
at a rate of 50 mL/min. Before any samples were analyzed, the instrument was calibrated 
for heat flow and temperature using indium and for heat capacity with aluminum and 
sapphire reference standards. Small samples (5-7 mg) were captured in aluminum pans 
and heated at a rate of 2 °C/min from -40 to 400 °C. TM-DSC parameters included an 
amplitude of 0.318 °C and a modulation period of 60 s. 
3.2.7 Thermal Gravimetric Analysis (TGA) 
 Further insight to the thermal integrity of silk fibers and films was studied by 
Thermal Gravimetric Analysis (TGA) using an SDT-Q600 TGA from TA Instruments 
with 100 mL/min nitrogen purge gas flow. Small (4-6 mg) samples were heated from 25-
800 °C at a rate of 10 °C/min while recording their mass. 
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3.2.8 Drug Release Study 
 Small (6 mg) triplicate samples of silk fibers and films were submersed in 40 mL 
of deionized water to stimulate the release of model drugs from the samples. Control 
samples of pure silk fibers and films without mode drugs were also immersed in water. 
Over the course of four days, 200 µL of the solution samples were soaking in was 
removed and placed into a 96 well plate for analysis later. These aliquots were taken at 
predetermined time points (15 min, 30 min, 45 min, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 12 h, 24 h, 
36 h, 48 h, 60 h, 72 h, 84 h, 96 h) to study the release kinetics of the model drugs from 
the biomaterials. Between sampling, well plates were covered to prevent contamination 
or loss of aliquots. After all aliquots were collected, the UV-visible absorbance of each 
was quantified using a SpectraMax i3x Plate Reader from Molecular Devices LLC. 
Readings were taken horizontally across each well with 10 readings spaced 0.57 mm 
apart. The specific wavelength for each set of model drugs varied depending on the 
lambda max of the drug, which was determined through absorbance testing across the 
UV-visible spectrum first. Once outliers were removed from the data, the remaining 
absorbance readings were normalized from 0 to 1 to compare the release kinetics across 
different model drugs and across fibers and films. A two sample Student’s T-Test was 
performed across fiber and film samples for each model drug in order to test for 
statistically significant release speeds. All samples were removed from deionized water 
and dried for 12 h at 60 ℃ after release testing to re-analyze them by FTIR. 
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3.3 Results and Discussion 
3.3.1 Structural Characterization 
 Structural properties of air-spun silk fibers both with and without embedded 
model drugs was initially studied using FTIR. Figure 3.2a depicts the full spectra for all 
samples. These spectra proved that the formic acid used for fabrication evaporated off 
during fiber spraying or drying afterwards evident by the lack of a C=O ketone peak in 
the 1745-1715 cm-1 region. All peaks show a relatively similar amplitude among all 
samples. 
 Special attention was given to the Amide I and II regions of the FTIR spectra to 
understand how material fabrication and addition of model drugs affected the protein 
structure of the silk fibers. This region, highlighted in Figure 3.2b, is frequently used to 
analyze the secondary structures of proteins. 86 Stretching vibrations between C=O 
molecules in the protein backbone are the main contributor to the amide I region, which 
ranges from 1600-1700 cm-1. There are also some minor contributions from C-C≡N 
deformation, C≡N stretching out-of-phase, and N-H in-plane stretching. The amide II 
region, meanwhile, is caused by IR absorption of an out-of-phase combination of 
vibrations of C-N stretching and N-H bending in-plane, which shows up between 1600-
1500 cm-1. 154 FTIR analysis on the silk fibers revealed an absorbance peak centered at 
1639 cm-1, which is indicative of intramolecular β-sheets suspended in a random coil 
network 153, 175-179. The addition of model drugs was able to produce some shifting of this 
peak (Figure 3.2b, embedded). Specifically, alcian blue and rhodamine B shift the 
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absorbance peak to 1641 cm-1 while rifampin shifts the peak to 1640 cm-1. Additional 
shoulders also appear at 1585 cm-1 and 1589 cm-1 for crystal violet and rhodamine B 
embedded fibers, respectively. Both of these absorbances are caused by the model drugs 
themselves based on FTIR spectra of aqueous solutions of the model drugs. 8 There is 
also an increased absorbance at 1720 cm-1 in some embedded samples. Absorptions at 
this wavenumber are indicative of C=O stretching of the protein backbone 180, 181 further 
supporting the idea of molecular interaction between model drugs and the silk protein 
structure. Alcian blue and rhodamine B are both very hydrophobic molecules with high 
log P values of 2.77 and 1.95, respectively, which suggest that hydrophobicity of the 
embedded molecules could play a role in driving the self-assembly of silk into ordered 
secondary structures. This is similar to the complex interactions that amine additives have 
to suppress or assist in protein interactions 182. By understanding the biophysical and 
chemical nature of therapeutic molecules, it may be possible to produce fine-tuned 
protein-based biomaterials by tailoring the molecular interactions between the protein 
structure and the biomaterial’s therapeutic load. 
 Silk fibers were soaked in water for 4 days to release the model drugs from them 
and then re-analyzed by FTIR. This analysis must be prefaced with the observation that 
water soaking causes a release of CaCl2 ions that were introduced by the solvent to act as 
plasticizers and prevent intermolecular β-sheet formation. Upon removal of these ions, 
silk is able to re-form its native intermolecular beta sheet structure 88, 154, 170. Therefore, 
this transition in protein structure is not a primary result of the model drugs releasing. 
FTIR spectra (Figure 3.2c) revealed this transition to be the case in this study. After a 
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four day soak, all silk nanofibers, with or without embedded model drugs, shifted from 
amorphous silk I structure to crystalline silk II structure based on the new absorbance 
peaks between 1622-1628 cm-1 153, 154. Other changes in the FTIR spectra include 
decreases in the characteristic peaks of crystal violet at 1585 cm-1 and rhodamine B at 
1589 cm-1 due to the release of most of the molecules from the fibers. The variance in 
absorbance peak for the silk fibers is more indication of molecular interactions between 
the model drugs and silk protein structure. Pure silk sees this absorbance peak centered at 
1624 cm-1, but the physiochemical properties, especially the hydrophobicity, of the model 
drugs impact the self-folding of silk protein into intermolecular β-sheets. Alcian blue, 
with the highest weight and the most hydrophobicity, restricts the formation of 
intermolecular β-sheets based on a smaller shift in its absorbance peak at 1628 cm-1. On 
the other hand, rhodamine B and indigo carmine, with lower hydrophobicity, and 
rifampin with a hydrophilic character, help facilitate the formation of intermolecular β-
sheets indicated by an absorbance peak at 1622 cm-1. These interactions are further 
evidence that the compatibility of molecules and proteins are a crucial aspect of 
designing tunable biomaterials with tailored mechanical properties or release 
mechanisms. When coupled with the high porosity, surface-area-to-volume ratio, and 






FTIR Spectra of Silk Fibers 
 
Note. FTIR spectra for silk and silk-drug fibers. (a) Full spectra of fibers before drug 
release. (b) Amide I and II regions shown to emphasized protein structure. (c) Amide II 
and II regions after release of model drugs. 
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 A parallel analysis was performed on silk films with and without embedded 
model drugs. The full spectra (Figure 3.3a) again shows the absence of a formic acid 
peak, indicating that excess formic acid CaCl2 solvent was evaporated during film 
formation or drying.  
 The amide I and II regions were again closely examined for changes in secondary 
protein structure (Figure 3.3b). Prior to water soaking, all film samples showed an 
absorbance peak centered at 1640 cm which is again indicative of amorphous silk I 
structure containing a majority of random coils and some intramolecular β-sheets. Crystal 
violet and rhodamine B showed their characteristic peaks again, indicating adequate 
embedment of the model drugs within the films. Unlike the fiber samples, there is no 
variance in absorbance. In the larger, nonporous, 2D geometry of silk films, the model 
drugs were unable to influence the self-assembly of silk enough to change their IR 
absorbance spectra. Because silk fibers differed with porous, 1D geometry, there was 
greater opportunity for the model drugs to interact with the silk protein structure, 
allowing for shifts in the IR spectra. The lack of interaction between model drugs and the 
protein structure in silk films leads to lower thermal stability and control of the model 
drug release, which is revealed in more detail during thermal analysis and drug release 
testing later in this study. 
 After soaking in water and release of the model drugs, the film samples all shift to 
a crystalline silk II structure with high content of intermolecular β-sheets based on their 
IR absorbance peak at 1622 cm-1 in Figure 3.3c. Like during their initial analysis, there is 
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no variation in secondary protein structure because the model drugs are unable to interact 
with the silk film protein structure well due to geometric constraints. This means the 
hydrophobicity and physicochemistry of the model drugs does not restrict the self-folding 
of silk into intermolecular β-sheets once CaCl2 ions are washed out by the water but 




FTIR Spectra of Silk Films 
 
Note. (a) Full spectra of silk-model drug thin films before drug release. (b) Amide I and II 
regions shown to emphasized protein structure. (c) Amide II and II regions after release 
of model drugs. 
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3.3.2 Thermal Analysis 
 To first understand the overall thermal integrity of the silk fibers and films with 
and without embedded model drugs, TGA was used. The respective thermograms for 
fiber samples are shown in Figure 3.4. Within the weight percentage thermogram (Figure 
3.4a) there is a small mass loss under 100 °C as excess water and solvent embedded in 
the fiber network is evaporated. There is then a gradual mass loss between 200-325 °C 
until major degradation begins. Once the samples reach 500 °C, major degradation slows 
or stops. By the end of the test at 800 °C, silk fibers maintain between 40-50% of their 
initial weight. 
 The effects of model drugs on the thermal stability was then studied. In embedded 
samples where the model drug pushed the protein structure towards higher β-sheet 
content (rifampin and indigo carmine), the onset of major degradation was delayed from 
230 °C to 280 °C. Rhodamine B, which also influenced the FTIR absorbance in the 
amide I region, did not delay major degradation, but was able to stabilize the fiber 
materials in another way by slowing the rate of degradation. This is better seen in the 
derivative graph (Figure 3.4b) by the wide, shallow peak in the major degradation region. 
(350 °C). Alcian blue-embedded fibers also saw a later onset of degradation and slower 
degradation rate when compared to silk alone; degradation onset in alcian blue-embedded 
fibers did not begin until 280 °C whereas silk alone began degrading at 230 °C. Crystal 
violet, which did not change the IR absorbance much, does not push degradation onset 
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TGA Thermograms of Silk-Model Drug Fibers 
 
 
Note. (a) Remaining weight percent of silk and silk-model drug fibers as they were 
heated to 800 °C. (b) Derivative of remaining weight percentage curves. 
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 Silk films were also analyzed in the same way as the fibers. All film samples 
generally showed less thermal stability than their fiber counterparts (Figure 3.5). There is 
less degradation under 100 °C, although this is simply because any water or excess 
solvent is captured inside the 2D geometry of the films and cannot evaporate off. The 
samples themselves degrade earlier than the fibers do with sample degradation beginning 
around 180 °C. The samples also degrade much faster, whether with or without model 
drugs, indicative by the sharp derivative peaks in Figure 3.5b. Crystal violet-embedded 
films were best able to resist this degradation by showing a slower, constant degradation 
up to 200 °C. There are several sharp changes in mass at low temperatures (150-200 °C) 
in the thermograms of the model drug-embedded films, indicating that the 2D film 
geometry was unable to protect the model drugs from high temperatures like the fibers 
did. This cross-checks against the FTIR analysis, where model drugs were unable to 
interact with the silk protein structure inside the 2D film geometry. Model drugs in the 
1D fibers, however, were able to interact with the silk protein during its self-assembly, 
which resulted in thermal protection. This is especially obvious in rifampin-embedded 
films. Rifampin is especially susceptible to thermal degradation with degradation as early 
as 183 °C and a cold storage requirement 183. This can be seen clearly as a sharp peak in 
Figure 3.5b, but rifampin-embedded fibers containing the same amount of the model drug 
do not contain this same peak. Because rifampin was unable to interact with the silk film 
protein structure, it was not protected from thermal degradation. Instead of embedding 
within a fibrous network and interacting with the self-folding of silk, rifampin instead sits 
in layers in the nonporous 2D films and is easily degraded as temperatures approach its 
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degradation temperature. Similar behaviors of fibrous networks protecting therapeutic 
loads has been reported in other studies 8, 36, 184. 
 Silk films also saw major degradation earlier than silk fibers did. Whereas fiber 
samples did not begin major degradation until 325 °C, films began degrading at 300 °C 
(Figure 3.5). The presence of model drugs influences the degradation rate of the samples 
in the major degradation region (325+ °C), although there are no trends or significantly 
different degradations like the fiber samples had. Regardless, rifampin, alcian blue, and 




TGA Thermograms of Silk-Model Drug Films 
 
Note. (a) Remaining weight percent of silk and silk-model drug thin films as they were 
heated to 800 °C. (b) Derivative of remaining weight percentage curves. 
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 More precise thermal analysis was then performed using DSC. Beginning with 
fiber samples again, all samples see an initial small endothermic peak centered around 50 
°C as excess solvent embedded within the fiber network evaporates (Figure 3.6a). This 
can be cross-referenced with the TGA thermograms, where silk fibers lost 5-10% of their 
initial mass as samples heated to 100 °C due to the evaporation of bound solvent. 
Although all of these peaks are roughly the same magnitude, they are slightly higher in 
samples embedded with rifampin, rhodamine B, and indigo violet- again the same model 
drugs that interacted with the protein structure of silk fibers. It is feasible that the 
interactions between the model drugs and the protein structure allowed more solvent into 
the fibrous network to bind to the protein. Between 250-350 °C, more endothermic peaks 
appear in all samples as degradation of the materials begins. Again, these temperatures 
correlate well to the degradation temperatures observed in the TGA thermograms. 
Rifampin-embedded silk fibers contain an additional peak near 155 °C which is likely 
connected to the degradation of the drug itself. 
 In comparison to the fibers, silk films have much noisier thermograms indicating 
lower thermal stability. This is further evidence that the model drug-silk protein 
interactions provide thermal stability, since these interactions were absent in the film 
FTIR spectra. Cross-referencing the TGA thermograms can help make sense of the noisy 
DSC thermograms. All of the model drugs except for crystal violet saw heavy 
degradation at 150 °C in TGA testing; as much as 0.5% mass/°C was lost from the film 
samples at this temperature. When translated to the DSC thermogram, this heavy 
degradation creates noise. Because of the nonporous 2D geometry of the films, the silk 
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protein structure was unable to protect most of the embedded drugs from thermal 
degradation in the same way the porous 1D fibers could. Crystal violet was the only drug 
protected from thermal degradation by the films. In addition to being the smallest model 
drug, crystal violet also contains a dimethylated aromatic tertiary amine which could 
interact with the carboxylic acids in the amino acids of the silk side chain. All of the 
larger model drugs with aromatic tertiary amines are diethylated, meaning crystal violet 
is also less sterically hindered than the other model drugs. Because of its smaller size and 
lower hindrance, it is not unreasonable that crystal violet can still have some biophysical 




DSC Total Heat Flow Thermograms of Silk-Model Drug Fibers and Films 
 
Note. Total heat flow graphs of silk and silk-model drug (a) fibers and (b) thin films. 
Exothermic is upward. 
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Further information about the thermal properties of the silk fibers was obtained by 
the reversing heat capacity thermograms produced by DSC (Figure 3.7a). Although some 
model drugs obscure glass transition temperatures (Tg), they can still be identified in pure 
silk fibers and most model drug-embedded fibers. The most easily distinguishable Tg is 
found in pure silk fibers between 200-225 °C. Rhodamine B, crystal violet, and alcian 
blue-embedded fibers are less distinguishable; rifampin and indigo carmine-embedded 
fibers have indiscernible Tgs. Since rifampin degrades at 183 °C, it is possible that its 
melting and evaporation obscures reversing heat capacity changes caused by a glass 
transition. Since rifampin and indigo carmine-embedded fibers retained more of their 
mass before major degradation compared to silk fibers alone, it is possible that these 
influences on the thermal integrity of the silk fibers also influenced the visibility of a Tg. 
Similarly, rhodamine B-embedded fibers showed a slow, steady decomposition in the 
TGA thermogram, showing that it too may also influence heat capacity and the visibility 
of a Tg. 
Although the reversing heat capacity thermograms of silk-model drug films are 
noisy like their heat flow graphs, some useful numbers can still be extracted from them 
(Figure 3.7b).  All of the samples show an early glass transition around 50 °C as solvent 
internalized within the films plasticized. There is a similar trend to the fibers where 
model drugs cause some obscuring of this Tg; in alcian blue, rifampin, and indigo 
carmine-embedded films, this obscurement makes the first Tg indiscernible. The film 
thermograms then move into the region where most of the drugs degrade, causing much 
noise and obscuring any useful changes in heat capacity. There is the possibility of a Tg 
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in pure silk films and crystal violet-embedded films at 175 °C where silk films typically 
undergo a glass transition 154, but all other samples are too noisy to detect a second Tg, if 
one occurs. Once again, this thermal instability and the degradation of the drugs is due to 
poor interaction between the model drugs and the silk protein structure because of 
geometric constraints in the film geometry. Within the porous geometry of the fibrous 
materials, however, silk is better able to protect the model drugs from thermal 
degradation. Beyond this noisy region of the thermograms, all films begin major 




DSC Reversing Heat Capacity Thermograms of Silk-Model Drug Fibers and Films 
 
Note. Reversing heat capacity of silk and silk-model drug (a) fibers and (b) thin films. 
Exothermic is upward. 
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Table 3.2 
Key Temperatures from Thermal Analysis of Silk-Model Drug Fibers and Films 

















Pure silk 175 299 36 182 286 
Alcian blue N/A 298 48 N/A 292 
Indigo 
carmine 
N/A 302 64 N/A 302 
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Rifampin N/A 301 54 N/A 297 
Crystal violet 179 299 41 177 291 
Rhodamine 
B 
183 306 39 N/A 283 
Note. Values obtained from DSC; Temperatures recorded in the middle of the curve for 
changes in heat flow (middle degradation) or heat capacity. 
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3.3.3 Morphology Discussion 
 SEM images were used to study the morphology of air-spun silk fibers and the 
effects of model drugs. The SEM images for silk fibers are pictured in Figure 3.8 for both 
pure silk fibers and model drug-embedded fibers at 100, 500, and 1000x magnification. 
Within all images, the fiber networks remain porous. Some aggregates of the model drugs 
are visible, but most of the network remains unaffected in its porosity by the addition of 
the model drugs. Based on this, the addition of model drugs at low weight percentages 
allows the fibers to maintain the beneficial morphology that makes fibrous materials 
valuable drug delivery vehicles. Further analysis was then done using ImageJ to measure 
the average diameters of the fibers. In all samples, with or without model drugs, the fiber 
diameters typically ranged from 4-9 μm. There are also some small, nanofiber scale fibers 




SEM Images of Silk-Model Drug Fibers 
 
Note. First row scale bars are 100 μm. Second and third row scale bars are 25 μm. 
 
 A similar analysis was also done on silk films. SEM images of the film surfaces 
were taken at 100, 500, and 2000x magnification (Figure 3.9). In all samples, there are 
few, if any, aggregates of the model drugs visible. The films show a smooth surface with 
even topography. Indigo carmine-embedded films showed the roughest topography, 
which was also the case in other studies of indigo carmine-embedded films 8. Since 
indigo carmine is the only anionic model drug used, there may be electrostatic 
interactions during fabrication that influence the surface roughness of the films. Despite 
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SEM Images of Silk-Model Drug Thin Films 
 
Note. Scale bars from top to bottom row: 250 μm, 50 μm, 10 μm. 
 
3.3.4 Drug Release Testing 
 Because of the interesting protein-drug interactions seen in the FTIR and thermal 
analysis, plus the insignificant impact of model drugs on fiber morphology, a drug release 
test was conducted to see if these interactions also influenced the release kinetics of the 
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model drugs from the biomaterials. The model drugs chosen were used because of their 
varying size, weight, hydrophobicity, charge, and water solubility (Table 1) in addition to 
their similarity to the pharmaceuticals on the market today. A few of the molecules used 
also have historical significance in medicine. Rifampin, for example, was previously used 
to treat tuberculosis 185 and has recently been a potential therapeutic for atopic dermatitis 
186.  Rifampin also exhibits anti-bacterial and anti-fungal activity, as does crystal violet 
187, 188. While oral delivery is the most common and easiest method of administration for 
most patients, rifampin is discouraged for oral use due to frequent off-target effects 189-191 
. This can be avoided by using more localized deliver methods, including topical 
delivery. Here, silk fibers can provide a mat for rifampin to be delivered in a form similar 
to a bandage. Each of the model drugs used in this study also absorb light in the UV-
visible spectrum, which allows for easy quantification of its release from the materials in 
an aqueous solution. The kinetics of model drug release was compared between 1D fiber 
geometry and 2D film geometry by using a two-sample T-test with an alpha significance 
level of 0.05. 
 The normalized release profiles of silk fibers and films embedded with model 
drugs are depicted in Figure 3.10a and Figure 3.10b, respectively. Normalization was 
performed with the maximum assumed to be the amount of drug released at 96 h; beyond 
this, there was not a significant release of the drugs. Since the release study was 
conducted in deionized water, the hydrophobicity of the model drugs played a large role 
in the trends seen. Rifampin, which is highly hydrophilic with a log P of -9.7, releases 
from both fiber and film samples nearly immediately (90%+ in 15 minutes). Despite this, 
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there is still a significant difference in release speeds because of the differing geometry 
that causes silk films to retain rifampin for a slightly longer amount of time (P=0.013). 
This may be due to the large surface-area-to-volume ratio of the fiber samples exposing 
the surface of the fibers to more water than the surface of the films. This allows for 
enhanced mass transfer 131, giving rifampin a quicker release from fiber samples than film 
samples. All other model drugs have a hydrophobic character, with indigo carmine 
having the lowest hydrophobic character (log P = 1.01). This low hydrophobic character 
caused indigo carmine to have the second quickest release out of the set of model drugs, 
but there was no significant difference in release speeds between the fibers and the films 
(P=0.072). Regardless, indigo carmine is retained by the silk fibers and films much 
better; films retain the drug for 12 h and fibers for 60 h. 
 Crystal violet, rhodamine B, and alcian blue all have a much more sustained 
release. Crystal violet and rhodamine B have similar release profiles, which is sensible 
given their similar log P values of 1.4 and 1.95, respectively. Like the indigo carmine-
embedded samples, rhodamine B and crystal violet also have comparable release kinetics 
regardless of the biomaterial geometry. For crystal violet, the P value between films and 
fibers is 0.101 and for rhodamine B the P value is 0.085. Both crystal violet and 
rhodamine B are retained within the biomaterial for at least 12 h, and then see a slower 
release from the biomaterial while maintaining a continuous and relatively linear profile 
until all of the drug is released. 
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 Alcian blue showed the slowest release out of this set of model drugs. This fits the 
hydrophobicity trend since alcian blue has a log P of 2.77. In addition, alcian blue is by 
far the largest, heaviest molecule which gives it the lowest water solubility. Statistical 
analysis showed that the biomaterial geometry had the strongest effect on release kinetics 
for alcian blue (P=0.00). In fiber samples, alcian blue had a slow, controlled release from 
the fiber network; 93% of alcian blue was retained over 36 h in silk fibers, but silk films 
release 19% of their embedded alcian blue is only 15 minutes. After 36 h, however, 
alcian blue does have an increase in its release speed from the silk fibers. This can be 
attributed to drug-drug interactions 36 where alcian blue interacts with itself to resist 
detachment from the silk fibers and dissolution into water. These interactions combined 
with the low solubility of the drug (1 mg/mL at 25 °C8) cause a slow release of alcian 
blue, especially early in the study when there are plenty of alcian blue molecules to 
interact with each other. The hydrophobic effect, which assist silk in its self-assembly 
through preferential folding of its hydrophobic amino acids, could also help slow the 
release of alcian blue in fibers where the porous geometry allows model drugs to better 
interact with the protein structure. Further evidence of this claim is given by the results of 
the post-soak FTIR spectrum (Figure 3.2c). In this analysis, there was the lowest shift 
towards intermolecular β-sheets compared to any of the other drugs. This implies that the 
size and hydrophobicity of alcian blue inhibited the ability of silk to self-assemble into 
intermolecular β-sheets while also protecting itself from water. Because silk films did not 
have these same interactions in the protein structure (Figure 3.3c), alcian blue was less 
protected by the silk protein structure and released from the films quicker than the fibers. 
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Figure 3.10 
Release Profiles from Silk-Model Drug Fibers and Films 
 
Note. Normalized release profiles of various model drugs from silk (a) fibers and (b) thin 




Statistical Values from Model Drug Release 
Model Drug Pearson 
Correlation 
T-Stat P(T≤t) 
Alcian blue 0.645 -5.781 0.00 
Indigo carmine 0.914 1.929 0.072 
Rifampin 0.488 2.792 0.013 
Crystal violet 0.971 1.740 0.101 
Rhodamine B 0.979 1.839 0.085 
Note. All probabilities are compared to a two tailed t Critical of 2.120 and an alpha 
significance level of 0.05. 
 
3.3.5 Mechanism of Interaction 
 Silk-based fibrous materials provide a potential platform for the delivery of 
therapeutic molecules based on the interactions seen in this study. Specifically, the 
porous 1D geometry of fibers, when combined with the physicochemical properties of the 
therapeutic, provide a means of fine-tuning the release kinetics of the therapeutic from 
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the fiber network. While the flat 2D geometry of silk films makes it harder for therapeutic 
molecules to interact with the silk protein structure, there are still differences in release 
kinetics compared to silk fibers, which make them another platform for specific drug 
delivery applications. Regardless, silk fibers can also provide additional benefits over silk 
films. The 1D geometry of the fibers allows molecules to infiltrate the porous network 
and interact with the self-assembling silk protein, which provides thermal protection 
(rifampin, rhodamine B, inidigo carmine) or slows their release from the fibers (alcian 
blue). These protective interactions are comparable to the hydrophobic effect. As silk 
proteins inside the biomaterials self-assemble into intermolecular β-sheets, especially in 
an aqueous environment, the chemical and physical properties of the embedded drugs can 
influence this folding. As a result, understanding the biochemical and biophysical 
interactions between a molecule and the protein structure can fine tune mechanical and 
thermal properties of the biomaterial as well as the release kinetics of the molecule from 
the biomaterial. In the flat, nonporous 2D geometry of silk films, model drugs are not 
able to interact with the protein structure as well as in the fiber networks. This prevents 
drug-protein interactions, resulting in lower thermal stability and less control of the 
release kinetics for the embedded silk films. These drug-protein interactions and their 
effects on the silk protein structure are illustrated in Figure 3.11. Other studies of silk-
based drug delivery vehicles have shown similar results where the β-sheets of silk II were 
important in regulating the release kinetics of embedded drugs 32, 174. . A major takeaway 
from this study is that diffusion and mass transfer properties alone not the only properties 
that dictate model drug release kinetics. In a protein-based drug delivery vehicle, the 
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biochemical and biophysical interactions between the protein structure and the choice of 
therapeutic molecule are also important to understand in order to create specifically-tuned 
drug delivery vehicles for a wide range of applications. 
 
Figure 3.11 
Mechanism of Interaction 
 
Note. Porous 1D fiber networks allow for the integration of model drugs, which then 
influence the self-folding behavior of silk protein. In flat 2D films, model drugs are 
unable to interact in the same way. As a result, fibers are able to protect embedded model 
drugs from thermal degradation and slow the release of the molecules from its structure. 
In thin films, the drugs are more susceptible to thermal degradation and there is less 
control over their release. 
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3.4 Conclusions 
 Within this study, air-spraying was used as a novel nano-microfiber creation 
method to create model-drug embedded silk fibers with high throughput without the need 
for a high voltage power source. Analysis of the air-spun fibers showed that the porous 
1D geometry created a network for model drugs to interact with the silk protein structure 
in order to tailor the release kinetics of the drugs and provide thermal protection. The 
release kinetics followed a trend with the hydrophobicity of the model drugs, which 
highlighted the importance of biophysical and biochemical properties when designing a 
protein-based drug delivery vehicle. This study found that the hydrophobicity of the 
model drugs impacted the self-assembly of silk protein in a matter similar to how the 
hydrophobic effect helps facilitate the native folding of silk. While these interactions 
were common and measurable within the fiber samples, the flat, 2D geometry of the films 
prevented these same interactions. As a result, embedded silk films had lower control 
over the release kinetics of the model drugs and lower thermal stability. By better 
understanding the biophysical and biochemical interactions between therapeutic 
molecules and the protein structure of silk biomaterials, it will be possible to create fine-






 The overall goal of this project was to showcase the potential of protein-based 
biomaterials for drug delivery applications. Chapter 1 gave an overview of proteins, 
polysaccharides, and their composites that are commonly used in biomaterials research. 
The potential of these biomacromolecules was then discussed, especially with respect to 
drug delivery applications. This study focused on thin films and nanofibers because of 
their ease of fabrication and differing geometries (1D nanofibers vs. 2D films). Chapter 2 
then explored the potential of corn zein thin films and nanofibers for the delivery of the 
topical therapeutic sodium citrate. Formic acid was used to dissolve a large amount of 
zein and up to 30 wt% sodium citrate into the same solution, which was then cast into 2D 
films or spun into 1D nanofibers using a novel air-spraying method. Air-spraying proved 
to be an easy, safe, and effective method for producing a large amount of nanofibers in a 
short amount of time compared to conventional methods like electrospinning. 
Additionally, the fabrication method was proven to be safe by biocompatibility assays 
and MTT assays with a human cell line. Most notably, this study revealed that sodium 
citrate could interact with the protein structure of corn zein nanofibers to shift the 
structure from a less stable random coil structure towards a more stable alpha helical 
structure based on FTIR and DSC analysis. In the 2D geometry of corn zein films, 
however, this same shift did not occur, indicating that biomaterial geometry is a critical 
factor in fine-tuning the release of sodium citrate from the biomaterial structure. A 
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statistical analysis confirmed a significantly different release profile between fibers and 
films for the same wt% of sodium citrate except for 30 wt% sodium citrate, which was 
revealed to lose its porous geometry in SEM analysis, thus likening its release to that of 
the 2D films. This study showed that corn zein can interact with therapeutic molecules to 
fine-tune the release of the therapeutics from them in a porous, 1D nanofiber network, but 
not in 2D films. Future studies with corn zein should focus on the biophysical and 
biochemical interactions in differing biomaterial geometries. 
 After the success of corn zein nanofibers, a parallel study was conducted using 
Bombyx mori silk and a variety of model drugs. Five different model drugs of varying 
weight, hydrophobicity, charge, and solubility were chosen to represent a range of 
pharmaceuticals in use today. Morphology and drug release studies showed similar 
results to the zein study; in the 1D, porous geometry of nanofibers, the model drugs were 
able to shift the protein structure of the silk nanofibers slightly in order to change their 
crystallinity (beta sheet content). Hydrophobic drugs were able to cause a bigger shift 
towards intermolecular beta sheets, indicating that the hydrophobic effect and protein 
self-folding mechanisms likely had influence. The more hydrophobic drugs were able to 
be folded away in the protein structure, protecting them from thermal degradation and 
slowing their release from the nanofiber mats. In 2D silk films, however, this shift in 
protein structure did not occur, resulting in less control of the release of model drugs 
from the film structure. While nanofibers showed an obvious relationship between 
hydrophobicity and release speed, this was not the case in films. 
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 The results of both studies indicate that diffusion is not the only driving force in 
the release of therapeutic molecules from biomaterials. The biophysical and biochemical 
interactions between therapeutic molecules and the protein backbone of biomaterials 
plays an equally important role in tailoring the release profile of the therapeutics. Because 
of this, the physicochemical nature of the therapeutics and the biomaterial backbone are 
important to understand when designing a drug delivery vehicle, as is the geometry of the 
biomaterial. With a better understanding of these mechanisms, new fabrication 
techniques can be created to specifically match up therapeutic molecules with protein 
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